{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:19:59Z","timestamp":1793233199259,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"XenoPort, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40263-016-0333-8","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T08:20:04Z","timestamp":1461054004000},"page":"443-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Neal","family":"Hermanowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Buchfuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Jaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendoline","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"333_CR1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.sleep.2010.07.007","volume":"11","author":"CJ Earley","year":"2010","unstructured":"Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med. 2010;11:807\u201315.","journal-title":"Sleep Med"},{"key":"333_CR2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","volume":"165","author":"RP Allen","year":"2005","unstructured":"Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286\u201392.","journal-title":"Arch Intern Med"},{"key":"333_CR3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.sleep.2009.03.007","volume":"11","author":"RP Allen","year":"2010","unstructured":"Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics. Sleep Med. 2010;11:31\u20137.","journal-title":"Sleep Med"},{"key":"333_CR4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0149-2918(04)90136-1","volume":"26","author":"L Abetz","year":"2004","unstructured":"Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. 2004;26:925\u201335.","journal-title":"Clin Ther"},{"key":"333_CR5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/01.wnl.0000287072.93277.c9","volume":"70","author":"JW Winkelman","year":"2008","unstructured":"Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology. 2008;70:35\u201342.","journal-title":"Neurology."},{"key":"333_CR6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.sleep.2010.11.007","volume":"12","author":"M Hornyak","year":"2011","unstructured":"Hornyak M, Sohr M, Busse M. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials. Sleep Med. 2011;12:186\u20139.","journal-title":"Sleep Med"},{"key":"333_CR7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.sleep.2014.12.024","volume":"16","author":"YW Cho","year":"2015","unstructured":"Cho YW, Song ML, Earley CJ, Allen RP. Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. Sleep Med. 2015;16:775\u20138.","journal-title":"Sleep Med"},{"key":"333_CR8","unstructured":"HORIZANT\u00ae prescribing information and medications guides 2013. Santa Clara, CA: XenoPort, Inc.; 2013. http:\/\/www.horizant.com\/ . Accessed 26 Jun 2015."},{"key":"333_CR9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+\/\u2212)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II: improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311:324\u201333.","journal-title":"J Pharmacol Exp Ther"},{"key":"333_CR10","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","volume":"48","author":"KC Cundy","year":"2008","unstructured":"Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48:1378\u201388.","journal-title":"J Clin Pharmacol"},{"key":"333_CR11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","volume":"72","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW, XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS. Neurology. 2009;72:439\u201346.","journal-title":"Neurology"},{"key":"333_CR12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","volume":"32","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32:159\u201368.","journal-title":"Sleep"},{"key":"333_CR13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/jcm7090282","volume":"7","author":"DO Lee","year":"2011","unstructured":"Lee DO, Ziman RB, Perkins AT, XP053 Study Group, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282\u201392.","journal-title":"J Clin Sleep Med"},{"key":"333_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.746217","volume":"29","author":"Y Inoue","year":"2013","unstructured":"Inoue Y, Hirata K, Uchimura N, et al. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin. 2013;29:13\u201321.","journal-title":"Curr Med Res Opin"},{"key":"333_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","volume":"32","author":"AS Walters","year":"2009","unstructured":"Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32:311\u201320.","journal-title":"Clin Neuropharmacol"},{"key":"333_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","volume":"35","author":"R Lal","year":"2012","unstructured":"Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165\u201373.","journal-title":"Clin Neuropharmacol"},{"key":"333_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/07853890.2015.1025825","volume":"47","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Lee DO, Buchfuhrer MJ, et al. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015;47:269\u201377.","journal-title":"Ann Med"},{"key":"333_CR18","author":"AY Avidan","year":"2016","unstructured":"Avidan AY, Lee D, Park M, et al. The effect of gabapentin enacarbil on quality of life and mood outcomes in a pooled population of adult patients with moderate-to-severe primary restless legs syndrome. CNS Drugs. 2016; doi: 10.1007\/s40263-016-0329-4 . [ePub ahead of print].","journal-title":"CNS Drugs"},{"key":"333_CR19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.sleep.2015.11.002","volume":"19","author":"DO Lee","year":"2016","unstructured":"Lee DO, Buchfuhrer MJ, Garcia-Borreguero D, et al. Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome. Sleep Med. 2016;19:50\u20136.","journal-title":"Sleep Med"},{"key":"333_CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","volume":"4","author":"RP Allen","year":"2003","unstructured":"Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health. Sleep Med. 2003;4:101\u201319.","journal-title":"Sleep Med"},{"key":"333_CR21","first-page":"135","volume-title":"Handbook of pain assessment","author":"MP Jensen","year":"1992","unstructured":"Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R, editors. Handbook of pain assessment. New York: The Guildford Press; 1992. p. 135\u201351."},{"key":"333_CR22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1553-2712.2003.tb01355.x","volume":"10","author":"PE Bijur","year":"2003","unstructured":"Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med. 2003;10:390\u20132.","journal-title":"Acad Emerg Med"},{"key":"333_CR23","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.pain.2011.07.005","volume":"152","author":"MA Ferreira-Valente","year":"2011","unstructured":"Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011;152:2399\u2013404.","journal-title":"Pain"},{"key":"333_CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121\u201332.","journal-title":"Sleep Med"},{"key":"333_CR25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","volume":"85","author":"RK Bogan","year":"2010","unstructured":"Bogan RK, Bornemann MA, Kushida CA, Tran PV, Barrett RW. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85:512\u201321.","journal-title":"Mayo Clin Proc"},{"key":"333_CR26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149\u201358.","journal-title":"Pain"},{"key":"333_CR27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0006-3223(02)01867-X","volume":"53","author":"CH Mallinckrodt","year":"2003","unstructured":"Mallinckrodt CH, Sanger TM, Dub\u00e9 S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53:754\u201360.","journal-title":"Biol Psychiatry"},{"key":"333_CR28","volume-title":"Statistics without maths for psychology using SPSS for Windows","year":"2004","unstructured":"Dancey CP, Reidy J, editors. Statistics without maths for psychology using SPSS for Windows. 3rd ed. London: Pearson, Prentice Hall; 2004.","edition":"3"},{"key":"333_CR29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajem.2005.08.007","volume":"24","author":"SL Bernstein","year":"2006","unstructured":"Bernstein SL, Bijur PE, Gallagher EJ. Relationship between intensity and relief in patients with acute severe pain. Am J Emerg Med. 2006;24:162\u20136.","journal-title":"Am J Emerg Med"},{"key":"333_CR30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1067\/mem.2001.118863","volume":"38","author":"EJ Gallagher","year":"2001","unstructured":"Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001;38:633\u20138.","journal-title":"Ann Emerg Med"},{"key":"333_CR31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0196-0644(96)70238-X","volume":"27","author":"KH Todd","year":"1996","unstructured":"Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27:485\u20139.","journal-title":"Ann Emerg Med"},{"key":"333_CR32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675\u201384.","journal-title":"Sleep Med"},{"key":"333_CR33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s13311-012-0139-4","volume":"9","author":"MJ Buchfuhrer","year":"2012","unstructured":"Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics. 2012;9:776\u201390.","journal-title":"Neurotherapeutics."},{"key":"333_CR34","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","volume":"61","author":"W Ondo","year":"2004","unstructured":"Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393\u20137.","journal-title":"Arch Neurol"},{"key":"333_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","volume":"5","author":"JW Winkelman","year":"2004","unstructured":"Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9\u201314.","journal-title":"Sleep Med"},{"key":"333_CR36","first-page":"81","volume":"33","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case\u2013control study. Sleep. 2010;33:81\u20137.","journal-title":"Sleep"},{"key":"333_CR37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.sleep.2010.09.018","volume":"12","author":"RR Edwards","year":"2011","unstructured":"Edwards RR, Quartana PJ, Allen RP, et al. Alterations in pain responses in treated and untreated patients with restless legs syndrome: associations with sleep disruption. Sleep Med. 2011;12:603\u20139.","journal-title":"Sleep Med"},{"key":"333_CR38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2377-11-28","volume":"11","author":"D Garcia-Borreguero","year":"2011","unstructured":"Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol. 2011;11:28.","journal-title":"BMC Neurol."},{"key":"333_CR39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/sleep\/16.4.327","volume":"16","author":"AS Walters","year":"1993","unstructured":"Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16:327\u201332.","journal-title":"Sleep"},{"key":"333_CR40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","volume":"12","author":"C Trenkwalder","year":"2013","unstructured":"Trenkwalder C, Bene\u0161 H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141\u201350.","journal-title":"Lancet Neurol"},{"key":"333_CR41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.sleep.2005.12.011","volume":"7","author":"L Abetz","year":"2006","unstructured":"Abetz L, Arbuckle R, Allen RP, et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med. 2006;7:340\u20139.","journal-title":"Sleep Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0333-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0333-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T20:59:53Z","timestamp":1567803593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0333-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0333-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}